Geron Corporation Advances in Myeloid Hematologic Malignancies Treatment

Geron Corporation, established in 1990 and based in Foster City, California, is a late-stage clinical biopharmaceutical company dedicated to the development and commercialization of therapeutics for myeloid hematologic malignancies. The company is currently focusing on imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials. This innovative drug aims to inhibit the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies, offering hope for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The progress of imetelstat through clinical trials represents a significant step forward in the battle against these challenging conditions.